The use of flexible ureterorenoscopy for the diagnosis (DFU) of suspected lesions in the renal pelvis, calyx and other segments of the collecting system is common in urology. This elegant work tries to use a systematization of the surgical access in order to evaluate the possibility of tumor spillage in other urinary segments, when handling is diagnostic or therapeutic in urothelial tumors.
6. Retrograde ureteroscopy was performed and the ureteral sheath was removed with the ureteroscope. Drainage consisted of a mono-J + bladder catheter which was both removed on D1-D2 if no fever or signifi cant bleeding was occurring. Mostly important, no patient received postoperative endovesical instillation (EVI) after DFU. RNU was performed after DFU, by open or laparoscopic access according to the surgeon's preference and bladder cuff excision without the endoscopic approach. Postoperative EVI began in March 2016.
All patients had preoperative endoscopic and tomographic staging to rule out metastases or multicenter tumors. Postoperative follow-up was performed according to the institution's protocol.
At the end, the patients were stratifi ed into two groups before the RNU: those who underwent DFU (DFU+) and those who did not (DFU-). In a total of 171 patients who underwent RNU, 93 were included in the protocol: 70 -DFU+ and 23 -DFU -.
There was no statistical difference when comparing the baseline criteria between the two groups: age, tumor stage and tumor grade, postoperative pain analysis or positive surgical margins.
At the 35-month postoperative follow-up, DFU+ patients had a bladder recurrence (BR) up to 87%. No risk factor for BR other than DFU was found in a multivariate statistical analysis.
Despite the technical care, the odds ratio for DFU+ was 4.0. However, as reported by the authors, BR presented neoplasms of less aggressive behavior, low risk and superfi cial diseases, even if multifocal. There was no long-term impairment in overall survival, cancer-specifi c survival, and metastasis-free survival.
The reference cited by the authors places as risk factors for BR the presence of previous bladder neoplasia, high-grade neoplasms, urinary cytology prior to the RNU (1). Even so, this multivariate analysis did not use DFU as a risk factor for BR. Thus, the authors interpreted that factors linked to primary neoplasia could be more determinant than DFU itself for the presence of BR.
As reported, many studies cite DFU but without elucidating its technique, presence of ureteric sheaths, or confi rmatory biopsy. Most importantly, in this study, all patients who had a history of previous resection of bladder neoplasms were excluded.
The authors also mention that despite RNU in high-grade urothelial tumors, intra-bladder recurrence was of low-grade neoplasms. This supports the need for further studies to decrease BR after DFU, such as intra-vesical chemotherapy, which is already performed after RNU.
